The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0842 ET – Hypera management expects the Brazilian pharmaceutical’s weak 3Q sales to be a temporary situation, say Citi Research analysts Leandro Bastos and Renan Prata in a research note. Citi trimmed its estimates for Hypera’s 2023-2024 earnings and cut its target price for the company’s shares to 36 reais, the equivalent of $7.20,after 3Q earnings were hit by a mild southern-hemisphere winter in Brazil that reduced demand for anti-flu medicines. Hypera management said in a recent conference call that it has a robust portfolio of leading brands, an innovation pipeline and growing production capacity, Citi says.([email protected])